Triptans, serotonin 5-HT1B/1D receptor agonists, represent a milestone in migraine therapeutics: they are effective acute attack therapies with a clear pharmacology and no substantial nonheadache indications.(1) Their mechanism of action has never been entirely defined despite widespread use and the potential utility for medicine development in understanding the effect.